
Bausch Health Companies Inc. (TSE:BHC – Free Report) – Analysts at Zacks Research raised their FY2026 earnings per share estimates for shares of Bausch Health Companies in a report issued on Wednesday, November 18th. Zacks Research analyst Team now expects that the company will post earnings of $7.11 per share for the year, up from their prior forecast of $5.95. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2028 earnings at $1.02 EPS.
Bausch Health Companies (TSE:BHC – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share for the quarter. The firm had revenue of C$4.19 billion during the quarter. Bausch Health Companies had a negative net margin of 7.43% and a positive return on equity of 57.67%.
Bausch Health Companies Stock Performance
Bausch Health Companies announced that its board has authorized a stock buyback plan on Wednesday, October 28th that authorizes the company to buy back C$70 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 1.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Insider Buying and Selling
In other Bausch Health Companies news, insider Mirza Dautbegovic sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the sale, the insider directly owned 224,745 shares of the company’s stock, valued at C$2,512,649.10. The trade was a 8.17% decrease in their ownership of the stock. Corporate insiders own 11.28% of the company’s stock.
More Bausch Health Companies News
Investors following BHC have been watching these news items:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $7.11 from $5.95 and its FY2027 estimate to $5.56 from $5.40. It also lifted estimates for several quarters in late 2026 and 2027, and nudged FY2028 EPS to $4.32 from $4.28. These upward revisions suggest improved expectations for much of the forecast period. Bausch Health Companies analyst estimates
- Negative Sentiment: Zacks lowered its Q3 2028 EPS estimate to $1.02 from $1.14, tempering the more favorable revisions elsewhere. The overall outlook remains mixed, and the estimate changes alone do not establish the reason for the share decline. Bausch Health Companies analyst estimates
Bausch Health Companies Company Profile
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Read More
- Five stocks we like better than Bausch Health Companies
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
